The small-molecule kinase inhibitor ceritinib, unlike imatinib, causes a significant disturbance of lipid membrane integrity: A combined experimental and MD study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The small-molecule kinase inhibitor ceritinib, unlike imatinib, causes a significant disturbance of lipid membrane integrity: A combined experimental and MD study
Authors
Keywords
-
Journal
CHEMISTRY AND PHYSICS OF LIPIDS
Volume 257, Issue -, Pages 105351
Publisher
Elsevier BV
Online
2023-10-18
DOI
10.1016/j.chemphyslip.2023.105351
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A recent update on small‐molecule kinase inhibitors for targeted cancer therapy and their therapeutic insights from mass spectrometry‐based proteomic analysis
- (2022) Pey Yee Lee et al. FEBS Journal
- Alterations in cellular metabolisms after Imatinib therapy: a review
- (2022) Veerandra Kumar et al. MEDICAL ONCOLOGY
- Recent progress in assays for GPCR drug discovery
- (2022) Shimeng Guo et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Drug–Membrane Interactions: Effects of Virus-Specific RNA-Dependent RNA Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid Bilayers
- (2022) Markus Fischer et al. BIOCHEMISTRY
- Regulation of membrane protein structure and function by their lipid nano-environment
- (2022) Ilya Levental et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Impact of Selected Small-Molecule Kinase Inhibitors on Lipid Membranes
- (2021) Meike Luck et al. Pharmaceuticals
- Visualizing and quantifying antimicrobial drug distribution in tissue
- (2021) Benjamin A. Kuzma et al. ADVANCED DRUG DELIVERY REVIEWS
- Membrane Trafficking and Subcellular Drug Targeting Pathways
- (2020) Ajay Kumar et al. Frontiers in Pharmacology
- Engineering the drug carrier biointerface to overcome biological barriers to drug delivery
- (2020) Joel A. Finbloom et al. ADVANCED DRUG DELIVERY REVIEWS
- Improving cellular uptake of therapeutic entities through interaction with components of cell membrane
- (2019) Renshuai Zhang et al. DRUG DELIVERY
- Intrinsic Membrane Permeability to Small Molecules
- (2019) Christof Hannesschlaeger et al. CHEMICAL REVIEWS
- Antitumor Activity and Combined Inhibitory Effect of Ceritinib with Gemcitabine in Pancreatic Cancer
- (2019) Muhammad Babar Jamshed et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Brain metastases in oncogene-driven non-small cell lung cancer
- (2019) Makoto Nishino et al. Translational Lung Cancer Research
- Solubility of Cyclodextrins and Drug/Cyclodextrin Complexes
- (2018) Phennapha Saokham et al. MOLECULES
- The interaction of sorafenib and regorafenib with membranes is modulated by their lipid composition
- (2016) Ivan Haralampiev et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- Biophysics in cancer: The relevance of drug-membrane interaction studies
- (2016) Ana Catarina Alves et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- Stimulation of Suicidal Erythrocyte Death by Ceritinib-Treatment of Human Erythrocytes
- (2016) Abdulla Al Mamun Bhuyan et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- The adrenal specific toxicant mitotane directly interacts with lipid membranes and alters membrane properties depending on lipid composition
- (2016) Holger A. Scheidt et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Ceritinib: a Review in ALK-Positive Advanced NSCLC
- (2016) Emma D. Deeks Targeted Oncology
- MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients
- (2016) S Harrach et al. Blood Cancer Journal
- CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field
- (2015) Jumin Lee et al. Journal of Chemical Theory and Computation
- OCT1 and imatinib transport in CML: is it clinically relevant?
- (2015) D B Watkins et al. LEUKEMIA
- FDA-approved small-molecule kinase inhibitors
- (2015) Peng Wu et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The Evolution of Therapies in Non-Small Cell Lung Cancer
- (2015) Vishal Boolell et al. Cancers
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) M. Reck et al. ANNALS OF ONCOLOGY
- Ceritinib
- (2014) Maryann R. Cooper et al. ANNALS OF PHARMACOTHERAPY
- CHARMM-GUIMembrane Buildertoward realistic biological membrane simulations
- (2014) Emilia L. Wu et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
- (2014) Puey Ling Chia et al. Clinical Epidemiology
- Cellular uptake, intracellular trafficking, and antitumor efficacy of doxorubicin-loaded reduction-sensitive micelles
- (2013) Can Cui et al. BIOMATERIALS
- Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)
- (2013) A. T. Nies et al. CLINICAL CANCER RESEARCH
- Rapid parameterization of small molecules using the force field toolkit
- (2013) Christopher G. Mayne et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- Targeting drugs to mitochondria
- (2012) Anne Heller et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Open Babel: An open chemical toolbox
- (2011) Noel M O'Boyle et al. Journal of Cheminformatics
- Drug-Membrane Interactions: Significance for Medicinal Chemistry
- (2010) M. Lucio et al. CURRENT MEDICINAL CHEMISTRY
- Update of the CHARMM All-Atom Additive Force Field for Lipids: Validation on Six Lipid Types
- (2010) Jeffery B. Klauda et al. JOURNAL OF PHYSICAL CHEMISTRY B
- The interaction of small molecules with phospholipid membranes studied by 1H NOESY NMR under magic-angle spinning
- (2009) Holger A Scheidt et al. ACTA PHARMACOLOGICA SINICA
- Effect of Membrane Composition on Antimicrobial Peptides Aurein 2.2 and 2.3 From Australian Southern Bell Frogs
- (2009) John T.J. Cheng et al. BIOPHYSICAL JOURNAL
- CHARMM-GUI Membrane Builder for Mixed Bilayers and Its Application to Yeast Membranes
- (2009) Sunhwan Jo et al. BIOPHYSICAL JOURNAL
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- (2009) Jorg Hartmann et al. CURRENT DRUG METABOLISM
- CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields
- (2009) K. Vanommeslaeghe et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- CHARMM: The biomolecular simulation program
- (2009) B. R. Brooks et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- Subcellular targeting strategies for drug design and delivery
- (2009) Lawrence Rajendran et al. NATURE REVIEWS DRUG DISCOVERY
- Interaction of imatinib with liposomes: Voltammetric and AFM characterization
- (2008) Victor C. Diculescu et al. BIOELECTROCHEMISTRY
- Characterization of the Interactions between Fluoroquinolone Antibiotics and Lipids: a Multitechnique Approach
- (2008) Hayet Bensikaddour et al. BIOPHYSICAL JOURNAL
- MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth
- (2008) Yuichi Takayama et al. CANCER LETTERS
- C-kit Inhibition by Imatinib Mesylate Attenuates Progenitor Cell Expansion and Inhibits Liver Tumor Formation in Mice
- (2008) Belinda Knight et al. GASTROENTEROLOGY
- CHARMM-GUI: A web-based graphical user interface for CHARMM
- (2008) Sunhwan Jo et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- Gastrointestinal stromal tumors and leiomyosarcomas
- (2008) Steven C. Katz et al. JOURNAL OF SURGICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started